| Literature DB >> 35103066 |
Samuel Baker Obakiro1,2,3, Ambrose Kiprop2,3, Isaac K'owino3,4, Moses Andima5, Richard Oriko Owor5, Robi Chacha6, Elizabeth Kigondu7.
Abstract
BACKGROUND: Albizia coriaria Welw ex. Oliver (Fabaceae) is one of the plants used by herbalists in the East Africa community to prepare herbal remedies for the management of symptoms of TB. Despite its widespread use, the antimycobacterial activity of this plant was uninvestigated and there was contradicting information regarding its cytotoxicity.Entities:
Year: 2022 PMID: 35103066 PMCID: PMC8800636 DOI: 10.1155/2022/7148511
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Extraction yield, minimum inhibitory, and cytotoxic concentrations of the extracts of A. coriaria stem bark.
| Extract | Percentage yield (%) | Minimum inhibitory concentration (mg/mL) | Cytotoxic concentrations ( | |
|---|---|---|---|---|
|
|
| Vero E6 cells | ||
| Hexane | 0.48 | NA | NA | >1000a |
| Chloroform | 0.73 | NA | NA | >1000a |
| Acetone | 23.0 | 1250 ± 0.0a | 937 ± 442a | >1000a |
| Methanol | 23.2 | 1250 ± 0.0a | 2500 ± 0.0a | >1000a |
| Rifampicin | — | 15 ± 0.0 | 4 ± 0.0 | 520.02 ± 40.11 |
Note: aP < 0.01 for extract vs rifampicin; NA: not active.
Results of the phytochemical screening of stem bark extracts of A. coriaria.
| Secondary metabolite | Extraction solvent | |||
|---|---|---|---|---|
| Hexane | Chloroform | Acetone | Methanol | |
| Saponins | − | − | ++ | + |
| Tannins | − | − | +++ | +++ |
| Alkaloids | + | ++ | ++ | ++ |
| Coumarins | ++ | + | +++ | + |
| Steroid glycosides | − | − | + | + |
| Triterpenes | + | +++ | +++ | + |
| Flavonoids | + | ++ | +++ | + |
| Emodols | − | − | − | − |
| Anthocyanins | − | − | +++ | ++ |
| Anthracenosides | − | − | +++ | − |
| Reducing sugars | − | − | +++ | ++ |
| Volatile oils | +++ | + | + | − |
Note: +++ (highly present), ++ (moderately present), + (little/traces present), and − (absent).
Chemical compounds identified in the acetone and methanol extracts of A. coriaria stem bark using GC-MS/MS analysis.
| RT (min) | Compound name | Chemical structure | Molecular formula | CAS# | Match factor | Area % |
|---|---|---|---|---|---|---|
| 8.667 | Hydroquinone ( |
| C6H6O2 | 123-31-9 | 71.5 | 10.91 |
| 9.1668 | Hexanal, (2,4-dinitrophenyl)hydrazine ( |
| C12H16N4O4 | 1527-97-5 | 52.5 | 0.45 |
| 9.2805 | 7-Hydroxy-3′-methoxyflavone, trimethylsilyl ether ( |
| C19H20O4Si | 1000448-98-1 | 52.2 | 3.65 |
| 10.5152 | Alpha-d-glucofuranose, 6-amino-6-deoxy-1,2: 3,5-bis-O-(1-methylethylidene) (4) |
| C12H21NO5 | 34322-93-5 | 53.8 | 4.41 |
| 12.6822 | Octadecanoic acid, 9,10-dichloro-, methyl ester ( |
| C19H36Cl2O2 | 33094-27-8 | 50.4 | 0.6 |
| 13.6985 | 3a,9b-Dimethyl-1,2,3a,4,5,9b-hexahydrocyclopenta[a]naphthalen-3-one ( |
| C15H18O | 76803-93-5 | 69.2 | 3.29 |
| 14.4482 | 2,2,4-Trimethyl-1,3-pentanediol diisobutyrate ( |
| C16H30O4 | 6846-50-0 | 75.8 | 22.1 |
| 15.0766 | 1H-Indene, 2,3-dihydro-4,5,7-trimethyl ( |
| C12H16 | 6682-06-0 | 51.7 | 0.54 |
| 17.0349 | 4,5-Dihydro-3-(4-pyridinyl)-2H-benz(g)indazole ( |
| C16H13N3 | 52837-55-5 | 57.4 | 0.96 |
| 18.8234 | 3,3,4-Tricyano-4a-methyl-2-phenyl-2,5,6,7-tetrahydro-1-benzopyran-4-carboxamide ( |
| C20H18N4O2 | 1000459-39-9 | 52.1 | 0.98 |
| 19.5301 | N,N′-Ethylenebis(2-[2-hydroxyphenyl]glycine) ( |
| C18H20N2O6 | 1170-02-1 | 55.1 | 1.03 |
| 20.0803 | 2-Myristynoyl pantetheine ( |
| C25H44N2O5S | 1000111-63-3 | 55.1 | 1.48 |
| 21.4324 | 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl)ester ( |
| C16H22O4 | 84-69-5 | 66.1 | 3.33 |
| 22.3127 | 7-Hydroxy-6,9a-dimethyl-3-methylene-decahydro-azuleno [4,5-b]furan-2,9-dione ( |
| C15H20O4 | 1000296-15-9 | 51.9 | 0.29 |
| 22.833 | Hexadecanoic acid, methyl ester ( |
| C17H34O2 | 112-39-0 | 88.3 | 49.44 |
| 23.4149 | Benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, methyl ester ( |
| C18H28O3 | 6386-38-5 | 59.3 | 3 |
| 23.8606 | 1,2-Benzenedicarboxylic acid, butyl 2-methylpropyl ester ( |
| C16H22O4 | 17851-53-5 | 84.6 | 100 |
| 25.1066 | Hexadecanoic acid, 14-methyl-, methyl ester ( |
| C18H36O2 | 2490-49-5 | 67.6 | 2.28 |
| 26.416 | 9,12-Octadecadienoic acid (Z,Z)-, methyl ester ( |
| C18H34O2 | 112-63-0 | 87.8 | 46.92 |
| 26.9327 | Methyl stearate ( |
| C19H38O2 | 112-61-8 | 82.8 | 21.11 |
| 28.0987 | Normorphine, 2TMS derivative ( |
| C22H33NO3Si2 | 55319-88-5 | 52.2 | 1.41 |
| 29.8072 | Eicosanoic acid, methyl ester ( |
| C21H42O2 | 1120-28-1 | 67.8 | 6.17 |
| 30.2999 | Octadecanal, 2-bromo-( |
| C18H35BrO | 56599-95-2 | 60.8 | 1.39 |
| 32.1471 | Docosanoic acid, methyl ester ( |
| C23H46O2 | 929-77-1 | 67.8 | 5.77 |
| 34.5468 | Tetracosanoic acid, methyl ester ( |
| C25H50O2 | 2442-49-1 | 67.5 | 6.68 |
| 36.4072 | Thiazolo [3,2-a]benzimidazol-3(2H)-one, 6,8-dimethyl-2-[[2-(trifluoromethyl)phenyl]methylidene] ( |
| C19H13F3N | 349497-82-1 | 56.2 | 3.06 |
| 37.1967 | l-Leucine, N-(2-chloroethoxycarbonyl)-N-methyl-,pentadecyl ester ( |
| C25H48CINO4 | 1000328-52-5 | 50.3 | 0.09 |
| 38.9061 | 5H-Cyclohepta[b]pyridine-3-carbonitrile, 6,7,8,9-tetrahydro-2-amino-4-(4-fluorophenyl) ( |
| C17H16FN3 | 327098-56-6 | 50.5 | 0.2 |
|
| ||||||
| 7.3899 | Methyl 3-hydroxytetradecanoate ( |
| C15H30O3 | 55682-83-2 | 56.6 | 3.27 |
| 8.3156 | 9-(3-Fluoro-phenyl)-12-imino-10,11-dioxa-tricyclo[6.2.2.0(1,6)]dodecane-7,7,8-tricarbonitrile ( |
| C19H15FN4O2 | 1000296-03-2 | 53.4 | 1.12 |
| 9.1287 | 2H-Pyran-3,4,5-triol, tetrahydro-2-methoxy-6-methyl ( |
| C7H14O5 | 14009-07-5 | 63 | 1.44 |
| 10.9244 | Doconexent ( |
| C22H32O2 | 6217-54-5 | 51.8 | 0.23 |
| 11.9629 | Beta-D-Glucopyranose, 1,6-anhydro ( |
| C6H10O5 | 498-07-7 | 71.7 | 14.44 |
| 12.8206 | Benzoic acid, 4-(acetyloxy)-3-methoxy-, methyl ester ( |
| C11H12O5 | 35400-19-2 | 64.6 | 4.02 |
| 13.5814 | 1-Oxaspiro[4.5]decan-3-carboxylic acid, 2-oxo-4-cyano-, ethyl ester ( |
| C13H17NO4 | 140650-86-8 | 56.5 | 1.01 |
| 14.454 | 2,2,4-Trimethyl-1,3-pentanediol diisobutyrate ( |
| C16H30O4 | 6846-50-0 | 72.1 | 11.82 |
| 17.3793 | Isoquinoline, 1-[3-methoxy-5-hydroxybenzyl]-1,2,3,4-tetrahydro-6-methoxy ( |
| C18H21NO3 | 84230-26-2 | 59.5 | 2.76 |
| 21.4361 | 1,2-Benzenedicarboxylic acid, butyl octyl ester ( |
| C20H30O4 | 84-78-6 | 56.1 | 0.71 |
| 22.8455 | Hexadecanoic acid, methyl ester ( |
| C17H34O2 | 112-39-0 | 85.1 | 38.26 |
| 23.4029 | Benzenamine, N,N'-(1,2-dimethyl-1,2-ethanediylidene)bis[2,6-dimethyl ( |
| C20H24N2 | 49673-40-7 | 54.1 | 0.6 |
| 23.8634 | Dibutyl phthalate ( |
| C16H22O4 | 84-74-2 | 82.6 | 46.72 |
| 25.107 | Hexadecanoic acid, 14-methyl-, methyl ester ( |
| C18H36O2 | 2490-49-5 | 58 | 1.05 |
| 26.5203 | 9-Octadecenoic acid (Z)-, methyl ester ( |
| C19H36O2 | 112-62-9 | 89.9 | 100 |
| 26.938 | Methyl stearate ( |
| C19H38O2 | 112-61-8 | 84.7 | 15.16 |
| 27.9188 | 7,10,13-Eicosatrienoic acid, methyl ester ( |
| C21H36O2 | 30223-51-9 | 58.5 | 1.57 |
| 30.3004 | Ethanol, 2-(9,12-octadecadienyloxy)-, (Z,Z) ( |
| C20H38O2 | 17367-08-7 | 53.4 | 0.92 |
| 32.4456 | 3',8,8′-Trimethoxy-3-piperidyl-2,2′-binaphthalene-1,1′,4,4′-tetrone ( |
| C28H25NO7 | 127611-84-1 | 51.9 | 0.86 |
Figure 1Chromatogram for the GC-MS/MS analysis of the crude acetone (a) and methanol (b) extract of Albizia coriaria. Acquisition parameters: oven, initial temp 70°C for 2 min, ramp 25°C/min to 150°C, 3°C/min to 200°C, 8°C/min to 280°C hold for 10 minutes. Injection auto 280°C, volume = 1 μL; split = 10 : 1; carrier gas = He; transfer temp 280°C; source temp 280°C; scan 50–600 Da; column: 30m × 250 μm × 0.25 μm.
Figure 2Chemical structures of the most abundant and bioactive∗ compounds identified by the GC-MS analysis in the acetonic and methanolic extract of Albizia coriaria.
Figure 3FTIR spectrum for the crude acetone (a) and methanol (b) stem bark.
The root mean square deviation (RSMD) and binding affinities of the redocked cocrystalized ligands.
| Target (PDB ID) | RMSD | Binding energy (kcal/mol) |
|---|---|---|
| Polyketide synthase 13 (5V3Y) | 0.8288 | −28.2653 |
| ATP synthase (3A4R) | 0.7076 | −37.9922 |
Figure 4Maps of the pose for cocrystalized ligand in the binding site of polyketide synthase (a) and redocked pose of cocrystalized ligand (cyan colour) superposed on the native ligand (grey colour) (b). Interactions of cocrystalized ligand in the binding site of polyketide synthase (c). Interactions of the redocked cocrystalized ligand with amino acid residues in the binding site of polyketide synthase (d).
Figure 5Maps of the pose of cocrystalized ligand in the binding of ATP synthase (a) and redocked pose of cocrystalized ligand (maroon colour) superposed on the native ligand (grey colour) (b). Interactions of cocrystalized ligand with amino acid residues in the binding of ATP synthase (c). Interactions of the cocrystalized ligand with amino acid residues in the binding site of ATP synthase (d).
Top five docked ligands from those identified by GC-MS analysis on two protein targets.
| SN | Polyketide synthase | ATP synthase | ||
|---|---|---|---|---|
| Ligand | Binding energy (kcal/mol) | Ligand | Binding energy (kcal/mol) | |
| 1 | 3′,8,8′-Trimethoxy-3-piperidyl-2,2′-binaphthalene-1,1′,4,4′-tetrone ( | −26.8626 | l-Leucine, | −28.7742 |
|
| ||||
| 2 | l-Leucine, N-(2-chloroethoxycarbonyl)-N-methyl-, pentadecyl ester ( | −22.1684 | Tetracosanoic acid, methyl ester ( | −28.3306 |
|
| ||||
| 3 | Docosanoic acid, methyl ester ( | −21.8569 | 1,2-Benzenedicarboxylic acid, butyloctyl ester ( | −26.6023 |
|
| ||||
| 4 | Eicosanoic acid, methyl ester ( | −21.2508 | Docosanoic acid, methyl ester ( | −25.9241 |
|
| ||||
| 5 | 7-Hydroxy-3′-methoxyflavone, trimethylsilyl ether ( | −20.1252 | Eicosanoic acid, methyl ester ( | −24.0608 |
|
| ||||
| 6 | Bedaquiline | −24.0017 | Bedaquiline | −22.9042 |
|
| ||||
| 7 | Isoniazid | −10.8307 | Isoniazid | −11.6257 |
|
| ||||
| 8 | Rifampicin | −17.5541 | Rifampicin | −18.5886 |
Figure 6Binding interactions of the top five identified compounds with polyketide-13 synthase.
Figure 7Binding interactions of the top five identified ligands with ATPsynthase.
Descriptors of absorption, distribution, metabolism, elimination, and toxicity (ADMET) of top docked compounds.
| Properties | Compound | |||||||
|---|---|---|---|---|---|---|---|---|
| 43 | 27 | 24 | 22 | 3 | 25 | 37 | Acceptable values | |
|
| ||||||||
| Water solubility (log | −5.25 | −7.22 | −7.08 | −6.47 | −7.10 | −7.80 | −4.91 | −2 to −4 |
| GI absorption | High | Low | Low | Low | low | Low | High | High |
| CaCO2 permeability (log | −4.920 | −4.722 | −5.047 | −4.964 | −4.863 | −5.103 | −4.673 | >−5.15 |
| P-gp substrate | No | No | No | No | No | No | No | No |
| P-gp I inhibitor | Yes | No | No | No | Yes | No | Yes | No |
| Log Kp (skin permeation) (cm/s) | −6.49 | −2.32 | −1.22 | −1.69 | −5.15 | −0.63 | −4.13 | <−5.0 |
| F20% | Low | High | High | High | Low | High | High | High |
| F30% | High | High | High | High | High | High | High | High |
|
| ||||||||
|
| ||||||||
| PPB (%) | 91.59 | 98.12 | 96.99 | 97.16 | 99.45 | 97.06 | 97.88 | <90 |
| BBB permeability | No | No | No | No | No | No | Yes | No |
| VD (L/kg) | 0.430 | 1.265 | 1.577 | 3.112 | 2.906 | 3.814 | 1.367 | 0.04–20 |
| Fraction unbound in plasma (%) | 0.856 | 2.066 | 1.763 | 1.311 | 0.912 | 1.095 | 1.608 | >5 |
|
| ||||||||
|
| ||||||||
| CYP1A2 inhibitor | No | Yes | Yes | Yes | Yes | Yes | Yes | No |
| CYP2C19 inhibitor | No | No | No | No | Yes | No | No | No |
| CYP2C9 inhibitor | Yes | Yes | No | No | Yes | No | Yes | No |
| CYP2D6 inhibitor | No | No | No | No | Yes | No | Yes | No |
| CYP3A4 inhibitor | Yes | Yes | No | No | Yes | No | No | No |
| CYP1A2 substrate | Yes | No | No | No | Yes | No | No | No |
| CYP2C19 substrate | No | No | No | No | No | No | No | No |
| CYP2C9 substrate | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| CYP2D6 substrate | No | No | No | No | Yes | No | No | No |
| CYP3A4 substrate | No | No | No | No | No | No | No | No |
|
| ||||||||
|
| ||||||||
| Total clearance (mL/min/kg) | 3.78 | 4.35 | 4.63 | 4.65 | 3.41 | 15.96 | 10.38 | >5 |
| Probability that half-life is less than 3 hours | 0.018 | 0.056 | 0.098 | 0.143 | 0.116 | 0.014 | 0.123 | <0.3 |
|
| ||||||||
|
| ||||||||
| Carcinogenicity (AMES toxicity) | Yes | No | No | No | No | No | No | No |
| Cardiovascular toxicity (hERG blockers) | No | No | No | No | No | No | No | No |
| Hepatotoxicity | Low | No | No | No | No | No | No | No |
| Skin sensitization | No | Yes | Yes | Yes | Yes | Yes | Yes | No |
|
| ||||||||
|
| ||||||||
| Number of hydrogen bond donors (N-H, O-H): 0 to 7 | Yes; 0 violation | Yes; 1 violation: log | Yes; 1 violation: log | Yes; 1 violation: log | Yes; 0 violation | Yes; 1 violation: log | Yes; 1 violation: log | Yes ≤ 2 violation |
| Number of hydrogen bond acceptors (N, O): 0 to 12 | ||||||||
| Molecular weight: 100–600 Da | ||||||||
| The logarithm of the n-octanol/water distribution coefficient (log | ||||||||
VD: volume of distribution, PPB: plasma protein binding, CL: renal clearance, F20%: human oral bioavailability 20%, F30%: human oral bioavailability 30%, and numbers correspond to the top docked compounds from Table 5. Acceptable values are according to software https://admetmesh.scbdd.com.
Figure 8The mechanism of reaction for the derivatization of samples with BSTFA and TMCS.